Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis

Sarcoidosis Clinical Trial

— GAMES  

Official title:

Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03259282
• Other study ID #: 35RC16_3046_GAMES
• Status: Completed
• First received: August 21, 2017
• Last updated: April 10, 2018
• Start date: March 7, 2017
• Est. completion date: March 22, 2017

Study information

• Verified date: April 2018
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Evaluation of the rate of achievement of serum protein electrophoresis (PPE) in diagnosis in a retrospective cohort of patients at Rennes University Hospital

Description:

In 50% of cases, sarcoidosis is associated with polyclonal hypergammaglobulinemia. The other forms have a normal gamma globulin level.

The level of gamma globulinemia has not yet been studied as an evolutionary predictive factor. Furthermore, there are disseminated granulomatoses sharing common characteristics with sarcoidosis, associated with Common Variable Immunodeficiency deficit (DICV) type Primary Immunodeficiency syndrome (DIP), thus occurring in hypogammaglobulinemic patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 78
• Est. completion date: March 22, 2017
• Est. primary completion date: March 22, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients newly diagnosed with sarcoidosis

Exclusion Criteria:

• Comorbidity responsible for a change in the level of gamma globulin

• Other etiology of granulomatosis

Related Conditions & MeSH terms

• Sarcoidosis

Intervention

Biological:
• Analysis of gamma globulin
Electrophoresis of proteins

Locations

Country	Name	City	State
France	CHU de Rennes	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Study of gamma globulin level present in the blood at the time of diagnosis of sarcoidosis on disease activity	Electrophoresis rates of serum proteins	Day 1
Primary	Study of gamma globulin level present in the blood at the time of diagnosis of sarcoidosis on the course of the disease	Electrophoresis rates of serum proteins	Day 1